Floatz logo

PEGFILGRASTIM

Soft-tissue Sarcoma

University of California, Irvineprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

103 Active assets in the Soft-tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
Inno-206
GI Innovation, Inc.
Phase 3BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2BB
FILGRASTIM
University of California, Irvine
Phase 3BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →